Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT00001406 |
| Other study ID # |
940079 |
| Secondary ID |
94-I-0079 |
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 21, 1997 |
Study information
| Verified date |
May 7, 2024 |
| Source |
National Institutes of Health Clinical Center (CC) |
| Contact |
Lori Penrod, R.N. |
| Phone |
(240) 627-3647 |
| Email |
lpenrod[@]niaid.nih.gov |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study will investigate how, why and under what conditions eosinophils (a type of white
blood cell) become activated and will examine their function in immune reactions. Eosinophil
counts often rise in response to allergies, asthma, and parasitic worm infections. They can
also go up in uncommon autoimmune conditions and, rarely, in association with tumors.
Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no
apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung
problems, heart disease or nerve damage caused by the release of toxic substances in these
cells into body tissues.
Patients 1 to 100 years of age with eosinophil counts greater than 750/ml or an abnormal
accumulation of eosinophils in the skin or body tissues may be eligible for this study. All
participants will have a thorough medical history, physical examination and blood tests.
Depending on the person's age and symptoms, other diagnostic tests may be done, including
specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a
treatment study, and no experimental treatments will be offered. Patients who require
treatment will receive standard medical care.
Certain other procedures may be requested solely for research purposes. All participants will
be asked to donate extra blood for laboratory studies investigating how immune cells and
other immune substances in the blood act to stimulate a rise in eosinophils. In addition,
some participants may undergo one or more of the following:
- Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes
in the patient's condition and eosinophil counts over time.
- Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and
in certain patients at other times when it is important to look directly at the newly
developing cells in the bone marrow. For this procedure an area of skin and bone is
anesthetized with xylocaine (an anesthetic similar to that used by dentists), and a very
sharp needle is used to sample the bone marrow for evaluation. Bone marrow biopsy and
aspiration can have side effects of pain and/or bleeding into the skin and soft tissues
at the site of the procedure. Rarely the area at the biopsy site can become infected,
and is treated with antibiotics.
- Genetic testing: Some of the blood drawn from you as part of this study will be used for
genetic tests. Genetic tests can help researchers study how health or illness is passed
on to you by your parents or from you to your children. Any genetic information
collected or discovered about you or your family will be confidential.
- Leukapheresis (only patients 18 years and older) to collect large numbers of certain
cells - In this procedure, whole blood is collected through a needle placed in an arm
vein. The blood circulates through a machine that separates it into its components. The
white cells are then removed and the rest of the blood is returned to the body, either
through the same needle used to draw the blood or through a second needle placed in the
other arm.
Description:
Study Description: This study is designed to collect data and clinical samples from
participants with elevated eosinophil counts in the peripheral blood or tissues or their
relatives to enhance our understanding of the mechanisms driving eosinophilia and eosinophil
activation in patients with a wide range of eosinophilic disorders with the ultimate goal of
improving diagnostics and identifying novel treatment modalities for these patients.
Eosinophilic participants will undergo an extensive clinical evaluation at baseline and at
least yearly thereafter focused on the identification of the cause of eosinophilia and the
presence of end organ manifestations. Blood, bone marrow, tissue, and/or body fluids will be
collected for research purposes at initial and follow-up visits to address broader questions
relating to the varied etiologies of eosinophilia, biomarkers of disease activity and
eosinophil activation, and the functional role of eosinophils in homeostasis and disease
pathogenesis. While this protocol is not primarily designed to study treatment of
eosinophilic patients, the clinical and immunological responses to therapy will be monitored.
This protocol will also allow clinical and laboratory evaluation of family members of
subjects with eosinophilia to help identify genetic causes of eosinophilia and to provide
controls for immunologic studies.
Objectives: Primary Objective: to understand the mechanisms driving eosinophilia and
eosinophil activation in patients with a wide range of eosinophilic disorders
Secondary Objectives:
1. To develop a diagnostic algorithm that accurately classifies eosinophilic patients by
underlying etiology
2. To determine the mechanisms underlying eosinophil activation and recruitment to the
blood and tissues
3. To understand the mechanisms of action of therapeutic agents used or in development for
the treatment of HES
4. To assess the signs and symptoms experienced by patients with HES
Exploratory Objectives:
1. To investigate the multifunctional role of eosinophils in settings other than HES
2. To understand the long-term effects of eosinophilia in patients with HES
3. To assess the effects of race, sex, ethnicity, and environmental factors on the
prevalence and clinical manifestations of eosinophilic disorders
Endpoints:
Primary Endpoint:
Identification and characterization of clinical and genetic variants of hypereosinophilic
syndromes (HES)
Secondary Endpoints:
1. Identification of laboratory and clinical tests that distinguish between clinical and
genetic variants of HES
2a. Identification of biomarkers of disease activity and specific organ involvement in
eosinophilic disorders
2b. Identification of new therapeutic targets for the treatment of HES
3. Delineation of the effects of therapeutic agents on eosinophil development, activation,
recruitment to tissues and/or apoptosis
4. Creation of a patient-related outcomes questionnaire for use in future treatment studies
of HES
Exploratory Endpoints:
1. Description of the consequences of eosinophilia and/or eosinophil depletion in the
context of varied immunologic and inflammatory
settings
2. Collection of standardized longitudinal data on disease activity and outcome in patients
with hypereosinophilia.
3. Comparison of prevalence and clinical manifestations of eosinophilic disorders among
varied subpopulations of patients
